Key takeaway: The investor presentation for Rossari Biotech Limited's Q2FY27 and H1FY27 results highlights strong financial performance, with consolidated revenue reaching Rs. 698 crores in Q2FY27, a 19% YoY increase, and Rs. 1,395 crores for H1FY27, up 23% YoY. Key business segments, including Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN), reported growth of 18%, 26%, and 11% respectively. The company maintained gross and EBITDA margins at ~32% and ~12.5%, despite challenges like raw material volatility and geopolitical uncertainty. Strategic initiatives include expanding international operations, such as leasing land in Saudi Arabia for a greenfield facility, and improving operational efficiency through better working capital management, with net working capital days reducing to 86 from 97. The presentation also outlines growth strategies focused on product innovation, market expansion, and strengthening the global footprint. The company emphasized its R&D capabilities, sustainable chemistry, and a diverse product portfolio as key drivers for long-term growth.

Key takeaway: During the earnings conference call held on July 20, 2026, management reported that Rossari Biotech Limited achieved its highest ever quarterly revenue and EBITDA for Q1 FY27, with consolidated revenue growing 28% year-over-year. The growth was attributed to strong domestic performance and international expansion. Management highlighted the importance of innovation, noting the ramp-up of a new R&D center and the launch of a Fibre Chemicals Division to enhance their textile specialty chemicals portfolio. The company also reported a 21% increase in export revenue. Despite challenges in the institutional and consumer segments, management expressed confidence in improving margins through portfolio rationalization and operational efficiency. EBITDA for the quarter was Rs. 80.6 crore, with margins at 11.6%. Management emphasized ongoing efforts to optimize asset utilization and enhance cash flows, aiming for sustainable growth and improved profitability.

Key takeaway: The investor presentation for Rossari Biotech Limited's Q1 FY27 results reported a consolidated revenue of Rs. 697.2 crore, reflecting a year-on-year growth of 28.2%. EBITDA for the quarter was Rs. 80.6 crore, with an EBITDA margin of 11.6%. Management highlighted strong performance in the HPPC, TSC, and AHN segments, each achieving approximately 28% growth year-on-year. The presentation noted that the institutional and B2C segments remained flat, with a focus on portfolio rationalization. Management emphasized the establishment of a new blending facility in Thailand to enhance international operations and improve supply chain efficiency. The company also reported progress in monetizing non-core assets, including the sale of its Andheri office. Overall, the management expressed confidence in the company's diversified business model and ongoing investments in innovation and operational efficiency.

Key takeaway: Management reported that Rossari Biotech Limited concluded FY26 with strong performance, achieving its highest-ever quarterly revenue and EBITDA in Q4. The company experienced a 15% revenue growth for the full year, primarily driven by volume increases across its business segments, despite facing external challenges such as raw material volatility and geopolitical disruptions. Management emphasized a focus on R&D and innovation, with the establishment of a new R&D facility in Navi Mumbai aimed at enhancing product development. The company also expanded its ethoxylation capacity to improve supply reliability. While the domestic market faced some softness, exports grew by 11% YoY. Management highlighted ongoing efforts to optimize costs and improve operational efficiencies, particularly in the institutional and B2C segments, which have been challenging. The company aims to maintain EBITDA margins between 12% to 13% in FY27, with a focus on higher-margin segments like pharma and animal health nutrition.

Key takeaway: The investor presentation for Rossari Biotech Limited reported strong financial performance for Q4 FY26, marking the highest quarterly revenue, EBITDA, and PAT in the company's history. Revenue from operations reached Rs. 684.9 crore, reflecting an 18.2% year-on-year increase. EBITDA stood at Rs. 77.3 crore, with an 11.3% margin, while PAT was reported at Rs. 46.0 crore, a 33.7% increase from the previous year. Management noted that core segments experienced robust growth, although performance in the Institutional and B2C segments remained subdued. The company emphasized ongoing optimization efforts and a focus on portfolio rationalization. Key developments included the commissioning of additional ethoxylation capacity and the establishment of a new R&D facility. The Board of Directors set a dividend of Re. 0.50 per share for FY26.